Progress in Rectal Cancer Treatment

Table 2

Interim results of randomized trials incorporating oxaliplatin in preoperative chemoradiation regimens.

Study	Treatment	𝑁	RT dose (Gy); Total/per fraction	pCR	SPS
STAR01 [56]	5-FU CIV	379	50.4/1.8	16%	80%
	5-FU CIV + OX 60 mg/m^2	368	50.4/1.8	16%	82%
ACCORD 12/0405-Prodige 2 [57]	CAP 800 mg/m^2	299	45/1.8	13.9%	75%
	CAP 800 mg/m^2 + OX 50 mg/m^2	299	50/1.8	19.2%	75%
CAO/ARO/AIO-04 [55]	5-FU; adj 5-FU	637	50.4/1.8	13.1%	88.1%
	5-FU + OX 50 mg/m^2; adj FolFox6	628	50.4/1.8	17.6%	87.8%
NSABP R-04 [58]	5-FU CIV ± OX 50 mg/m^2	719	50.4/1.8	18.8%	61.2%
	CAP 825 mg/m^2 ± OX 50 mg/m^2	707	50.4/1.8	22.2%	62.7%

CAP: capecitabine; RT: radiotherapy; pCR: pathological complete response; SPS: sphincter preserving surgery.